Mayo Clinic researchers identify proteins linked to immunotherapy resistance in metastatic colorectal cancer
Dubai, United Arab Emirates; May, 2025 — A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer. In findings published in Clinical Cancer Research, the team identified specific proteins — fibronectin and smooth muscle actin — within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.
Immunotherapy is a major advance in treating cancer, but many patients, including those with metastatic colorectal cancer, do not respond to it. Until now, researchers have not known why.
'We need predictive biomarkers to guide the selection of immunotherapy for patients,' says medical oncologist and gastroenterologist Frank Sinicrope, M.D. , the senior author of the study. 'Identifying those who may have resistance to treatment can be useful because then we can spare them from receiving treatment that may not be beneficial and could produce significant toxicities.'
The research team used digital spatial profiling, an advanced technology that simultaneously analyzes the expression of multiple proteins and where they are located within tissues. This approach allowed researchers to zoom in to get a bird's eye view of a tumor that includes proteins both within and surrounding the tumor cells and how they interact.
Dr. Sinicrope compares the spatial tools to an aerial view of a neighborhood where one can see relationships between driveways, houses, yards and neighboring structures. Similarly, this detailed view provides physicians and researchers with critical information about the proteins in and around a patient's cancer, potentially informing the best treatment for the patient.
'We wanted to learn more about the patients who did not respond to immunotherapy. We investigated the leading edge of the tumor where cancer cells are invading and where the immune system is attempting to fight the cancer,' says Dr. Sinicrope. 'It's like a battle going on here and we're getting a snapshot into who is in attendance.'
The researchers focused on 10 regions at the invasive margin of a tumor. They applied digital spatial profiling to investigate 71 distinct proteins in both the tumor's epithelial compartment and the surrounding stromal compartment. Fibronectin and smooth muscle actin are two extracellular matrix proteins that were found in the epithelial region of the tumor and were associated with resistance to immunotherapy and shorter time before disease progression.
Upon further analysis, the researchers observed that cancer-associated fibroblasts were producing these proteins. The evidence, they say, suggests that these proteins can contribute to suppression of the anti-tumor immune response.
The discovery offers a step toward more personalized and effective colorectal cancer treatments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
24-05-2025
- Mid East Info
Your abdominal core: Expert shares tips for protecting a part of the body you may not think about
Dubai, United Arab Emirates; May, 2025 — It is a large part of the body that lies deep inside, out of sight and perhaps out of mind: your abdominal core. A new and rapidly developing area of medicine focuses on abdominal core health, including how people can incorporate it into a healthy lifestyle and how to address complex medical problems that arise when it is compromised. Dr. Charlotte Horne, a metabolic and abdominal wall reconstructive surgeon at Mayo Clinic, explains what abdominal core health is, how to protect it and risk factors for problems that may require surgery. 'The abdominal core is the outside muscular container of your abdominal wall,' Dr. Horne says. 'This starts at the diaphragm and goes all the way down to the pelvic support muscles. Most of the core is muscle and connective tissue. It's a muscular container that holds your internal organs in. Every time you breathe, bend, bear down to have a bowel movement, you're using these muscles.' The abdominal core includes abdominal muscles that people may think of as the 'six-pack,' and oblique muscles and tissue that wrap all the way around the upper part of the abdomen and connect to the midline of the body, Dr. Horne adds. Many nerves lie between the layers of muscle and tissue, including those that extend to the groin, thighs, back and hips. Those muscles function as a unit and that unit needs to operate well for you and your body to perform daily activities, Dr. Horne says. One way to strengthen the structural integrity of your abdominal core is to engage it during your normal activities, she explains: You do not have to do thousands of sit-ups or become a bodybuilder. 'One of the things we're realizing is that we need to educate people how to appropriately engage those muscles when they do everything from going from lying to sitting and sitting to standing, lifting objects and other basic movements in their daily lives,' she says. 'When people do yoga or Pilates, they think about pulling their belly button into their spine. That helps stabilize the deeper muscles of the abdominal wall.' Improving abdominal core health involves conscious engagement of the abdominal muscles, 'bringing everything in and holding it in,' Dr. Horne says. Risk factors for abdominal core problems are wide-ranging. They include cancer treatment; inflammatory bowel disease; chronic or severe coughing; and complications from pregnancy (diastasis recti) and surgery. The most common problems are hernias, when part of an organ or tissue bulges through a weak spot in muscle. 'Coughing can cause large hernias. When you're coughing, you're bearing down and there is a sudden, acute change in intra-abdominal pressure, almost like punching from the outside in or from the inside out,' Dr. Horne explains. 'When you're doing that all of the time, it causes significant stress to your abdominal wall.' Avoiding smoking and excessive alcohol consumption can help protect abdominal core health. Smoking increases the risk of chronic coughing, while heavy alcohol consumption to the point of cirrhosis can cause hormonal changes that in turn weaken the abdominal wall, Dr. Horne says. As knowledge about abdominal core health grows, approaches to protecting it and healing it are advancing, Dr. Horne says. For example: Pregnancy causes muscles to expand to accommodate a baby, and sometimes those muscles do not go back to normal. Exercise regimens during and after pregnancy can help to stabilize them. Healthcare experts are realizing that restrictions on movement after surgery may not help and sometimes may be harmful. Rather than telling people not to lift anything, it may be more appropriate to explain how to safely reengage those muscles and tendons, Dr. Horne suggests. People with inflammatory bowel disease are likelier to have surgery and therefore are likelier to develop hernias. Surgeons now know that in those patients, mesh should be placed in different anatomic planes to prevent the mesh from touching the bowel and potentially causing problems later, Dr. Horne says. Pelvic floor physical therapy can help women experiencing urinary or fecal incontinence after pregnancy or menopause, she says. There is growing recognition that mesh used to repair hernias isn't one-size-fits-all. Dr. Horne's research focuses on hernia repair in women, including mesh and mesh techniques. In her practice, Dr. Horne specializes in complex hernia surgeries. 'Most of the patients that I care for have more of their abdominal contents outside of their abdominal cavity than inside,' she explains. Even with hernias as large as 10 to 15 centimeters, surgeries can be performed with a robot to minimize the incision, or can be done with a mix of robotic surgery and minimal open surgery, Dr. Horne says. She uses 3D-printed models to help plan surgeries. Sometimes Botox is used to lengthen the abdominal wall muscles, she adds. 'The best part is that patients go from a dysfunctional abdominal wall to one that is functional within about a week in the hospital,' Dr. Horne says. 'Seeing them at their checkup a year later is the best thing because they go from saying `I couldn't do anything' to `I've gone on all these trips, I've done all these things that I've wanted to do for years but haven't been able to.' They are so happy that they can put that whole thing behind them, which is great.'
Mid East Info
16-05-2025
- Mid East Info
Mayo Clinic manufacturing engineers on the cusp of delivering new biotherapies - Middle East Business News and Information
Dubai, United Arab Emirates, May, 2025 — Manufacturing engineers are at the forefront of bringing new medicines derived from human sources such as cells, blood and genes to patients. They produce what are often first-of-their kind biotherapies for diseases that previously had few or no treatment options. 'The most interesting thing about our job is being able to be part of a team that brings transformative cell-based therapies to the clinic,' says Kyle Ecker, advanced biomanufacturing engineer supervisor at Mayo Clinic in Florida. 'It's incredibly fulfilling to understand the scientific basis of these therapies and watch them come to life by manufacturing products for individual patients.' Mayo Clinic's Center for Regenerative Biotherapeutics has 40 manufacturing engineers in Rochester and Florida. Their work makes it possible for researchers to conduct studies that require cells to be engineered on a very short timeline. In some cases, they've been able to have cells taken from patients, manufactured and returned to them in a few weeks or less. Chimeric antigen receptor (CAR-T) cell therapy for B-cell cancers and a cell-based vaccine for ovarian cancer are two examples of experimental biotherapies manufactured at Mayo Clinic. 'Our engineering teams are very dedicated to patients. They know the importance of their job, and that's to get these drugs manufactured successfully so they can be given to patients in clinical trials,' says Snigdha Rai, senior director of advanced biomanufacturing in the Center for Regenerative Biotherapeutics. 'Without the engineers there would be no biomanufacturing and no cell and gene therapies for patients.' Manufacturing engineers work within a highly controlled laboratory setting or 'clean room.' Clean rooms are facilities that operate according to current Good Manufacturing Practice (cGMP) regulations to ensure therapies are consistently manufactured and meet strict quality standards. These controlled environments have powerful purification systems to filter out pollutants such as dust, airborne particles, bacteria, fungus and mold that could compromise drug safety. Adherence to strict cleanliness guidelines dictates how engineers do their job. Before stepping into a clean room, they train extensively how to operate in a cGMP facility without triggering contamination. They perform techniques to keep everything extremely clean or sterile, using high dexterity skills such as taking the cap off a vial and putting it back on with one hand, while the other hand fills it with a chemical compound. They dress in coveralls or a 'bunny suit' with a hood, goggles, face shield, double gloves and boot covers to block any escape of hair or skin cells. Once they've entered the clean room, their movements are slow and intentional. 'Rapid movements or quick opening of doors could trigger the sensors that monitor for microscopic particles,' Ecker explains. 'People and materials must flow in a specific path to prevent any type of contamination. For example, we move in one direction, entering the clean room through one door while exiting through a separate door.' Manufacturing engineers have the pivotal role of being the first to run processes that transform a cell and gene therapy from a discovery into experimental medicine for use in human clinical trials. They strictly follow standard operating procedures — a blueprint of sorts — to mass produce a new therapy. A minimum of two engineers work together at all times to ensure all cells are processed according to regulatory and quality standards. 'The team works very closely each step of the way. We check each other's work and keep detailed records confirming that all procedures have been completed,' says Qing Cindy Shao, Ph.D., lead advanced biomanufacturing engineer. 'There is no room for error.' An important function of the job is identifying when a procedure doesn't work as intended. The therapy is then sent back to the investigator and process development group to troubleshoot the issue and make appropriate changes. On-site manufacturing facilities make it possible to address the errors early and resolve them quickly. That helps minimize delays for patients. 'Our manufacturing engineers are indispensable. They work with quality control, quality assurance and process development to ensure the therapy meets the requirements and are safe for patients,' says Alina Oancea, manager of cGMP manufacturing. 'When the processes work as intended, it takes about two weeks to manufacture a CAR-T cell product.' Engineers' shifts in a clean room could range from three to 10 hours depending on the project they are working on. When they've completed their process for the day, they turn off the equipment, clean up the space and dispose of biowaste. Their work plays a central role in Center for Regenerative Biotherapeutics' strategy of biomanufacturing new cell and gene biotherapies and collaborating with industry to make them available to patients around the world. About Mayo Clinic: Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
Mid East Info
13-05-2025
- Mid East Info
Mayo Clinic researchers identify proteins linked to immunotherapy resistance in metastatic colorectal cancer
Dubai, United Arab Emirates; May, 2025 — A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer. In findings published in Clinical Cancer Research, the team identified specific proteins — fibronectin and smooth muscle actin — within colorectal cancer tissues that are associated with resistance to immunotherapy treatment. Immunotherapy is a major advance in treating cancer, but many patients, including those with metastatic colorectal cancer, do not respond to it. Until now, researchers have not known why. 'We need predictive biomarkers to guide the selection of immunotherapy for patients,' says medical oncologist and gastroenterologist Frank Sinicrope, M.D. , the senior author of the study. 'Identifying those who may have resistance to treatment can be useful because then we can spare them from receiving treatment that may not be beneficial and could produce significant toxicities.' The research team used digital spatial profiling, an advanced technology that simultaneously analyzes the expression of multiple proteins and where they are located within tissues. This approach allowed researchers to zoom in to get a bird's eye view of a tumor that includes proteins both within and surrounding the tumor cells and how they interact. Dr. Sinicrope compares the spatial tools to an aerial view of a neighborhood where one can see relationships between driveways, houses, yards and neighboring structures. Similarly, this detailed view provides physicians and researchers with critical information about the proteins in and around a patient's cancer, potentially informing the best treatment for the patient. 'We wanted to learn more about the patients who did not respond to immunotherapy. We investigated the leading edge of the tumor where cancer cells are invading and where the immune system is attempting to fight the cancer,' says Dr. Sinicrope. 'It's like a battle going on here and we're getting a snapshot into who is in attendance.' The researchers focused on 10 regions at the invasive margin of a tumor. They applied digital spatial profiling to investigate 71 distinct proteins in both the tumor's epithelial compartment and the surrounding stromal compartment. Fibronectin and smooth muscle actin are two extracellular matrix proteins that were found in the epithelial region of the tumor and were associated with resistance to immunotherapy and shorter time before disease progression. Upon further analysis, the researchers observed that cancer-associated fibroblasts were producing these proteins. The evidence, they say, suggests that these proteins can contribute to suppression of the anti-tumor immune response. The discovery offers a step toward more personalized and effective colorectal cancer treatments.
